Advair Reduces Exacerbations In COPD Patients

Armen Hareyan's picture

The use of Advair Diskus 250/50 (fluticasone propionate and salmeterol inhalation powder) demonstrated a 30% reduction in exacerbations in patients with chronic obstructive pulmonary disease (COPD) who have a history of exacerbations as compared with salmeterol alone, according to new data presented today at the International Conference of the American Thoracic Society meeting in Toronto.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.